While the dual BCL-XL and BCL-2 inhibitor, Navitoclax, has been evaluated clinically for non-CNS malignancies54, it is dose-limited by the “on-target, off-tumour” toxicity in platelets (thrombocytopenia). Here, BCL2L1 is linked to Thrombocytopenia.